Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 0.76 |
| ▸ | FES | P07332 | 1/20 | 0.76 |
| ▸ | FER | P16591 | 1/20 | 0.76 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.76 |
| ▸ | TEC | P42680 | 1/20 | 0.76 |
| ▸ | CLK1 | P49759 | 1/20 | 0.76 |
| ▸ | JAK3 | P52333 | 1/20 | 0.76 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.76 |
| ▸ | BTK | Q06187 | 1/20 | 0.76 |
| ▸ | TNK1 | Q13470 | 1/20 | 0.76 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4171719 | 0.94 | EGFR (1.00) | EGFRGAKFESFERERBB3 | |
| SCHEMBL18970175 | 0.93 | EGFR (0.86) | EGFRGAKFESFERERBB3 | |
| SCHEMBL4170760 | 0.91 | EGFR (1.00) | EGFRGAKFESFERERBB3 | |
| SCHEMBL18778504 | 0.91 | EGFR (0.83) | EGFRGAKFESFERERBB3 | |
| SCHEMBL30733360 | 0.89 | EGFR (0.84) | EGFRGAKFESFERERBB3 | |
| SCHEMBL17002256 | 0.88 | EGFR (0.88) | EGFRGAKFESFERERBB3 | |
| SCHEMBL2730294 | 0.87 | EGFR (1.00) | EGFRGAKFESFERERBB3 | |
| SCHEMBL17059607 | 0.87 | EGFR (1.00) | EGFRGAKJAK3PTK2BTK | |
| Rociletinib SCHEMBL4177736 | 0.86 | EGFR (1.00) | EGFRGAKFESFERERBB3 | |
| SCHEMBL4165885 | 0.86 | EGFR (1.00) | EGFRGAKFESFERERBB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10300058-B2 | Tyrosine kinase inhibitor and uses thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2019-05-28 | — | — | US | disclosed |
| US-10300058-B2 | Tyrosine kinase inhibitor and uses thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2019-05-28 | — | — | US | disclosed |
| WO-2017097113-A1 | AMINOPYRIMIDINE COMPOUNDS FOR INHIBITING ACITIVITY OF PROTEIN TYROSINE KINASE | 深圳市塔吉瑞生物医药有限公司 | 2017-06-15 | — | — | WO | disclosed |
| US-20170112833-A1 | Tyrosine Kinase Inhibitor And Uses Thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2017-04-27 | — | — | US | disclosed |
| US-20170112833-A1 | Tyrosine Kinase Inhibitor And Uses Thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2017-04-27 | — | — | US | disclosed |
| WO-2015158310-A1 | TYROSINE KINASE INHIBITOR AND USES THEREOF | 山东轩竹医药科技有限公司 | 2015-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170112833-A1 | Tyrosine Kinase Inhibitor And Uses Thereof | EGFR, ERBB2, ABL1 | EGFR 1/4885GAK 372/4885FES 232/4885 |
| US-10300058-B2 | Tyrosine kinase inhibitor and uses thereof | EGFR, ERBB2, ABL1 | EGFR 1/4885GAK 372/4885FES 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.